FDA Approves Supplemental Application for PURIXAN by Nova Labs
The FDA has approved a supplemental application for PURIXAN, an antimetabolite containing mercaptopurine, submitted by Nova Labs.
Asset / Drug
Drug and asset intelligence for PURIXAN with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.